Mechanism(s) Underlying Cardiovascular Effects of ARB/NEP Inhibition - Aim 2

This study tests the hypothesis that endogenous bradykinin contributes to effects of a combined angiotensin receptor blocker/neprilysin inhibitor (LCZ696 or Entresto)

Study Overview

• Status: Withdrawn
• Conditions: Heart Failure NYHA Class II; Heart Failure NYHA Class III; Heart Failure NYHA Class I
• Intervention / Treatment: Drug: Valsartan 80 mg bid; Drug: Enalapril 10 mg bid; Drug: Sacubitril-Valsartan 200 mg bid; Drug: Icatibant; Drug: Placebo

Detailed Description

Patients with heart failure (HF) with reduced ejection fraction who qualify for the study will undergo a three-week run-in period in which any prior angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker they were taking will be discontinued and they will be given valsartan 80 mg bid in a single-blind fashion. After the run-in, subjects will undergo four study periods in random order. During two study periods they will receive enalapril 10 mg bid and during two they will receive sacubitril/valsartan (LCZ696) 200 mg bid for seven days. On the seventh day or each period, subjects will complete a study day in which they are randomized to receive either the bradykinin B2 receptor blocker icatibant or placebo intravenously. Each study period will be separated by a three-week washout during which subjects receive valsartan 80 mg bid.

• Study Type: Interventional
• Phase: Phase 2

Contacts and Locations

Study Locations

• United States
  • Tennessee
    • Nashville, Tennessee, United States, 37232
      • Vanderbilt University Medical Center

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 75 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. Stable patients with a reduced EF

   1. EF less than or equal to 40% (confirmed by echocardiogram within the last six months), and
   2. history of symptoms of New York Heart Association class I, II or III HF
   3. stable clinical symptoms including no hospitalizations for the last six months
   4. treatment with a stable dose of an ACEi or ARB and with a beta blocker (unless contraindicated or not tolerated) for at least four weeks
   5. treatment with a stable dose of an MR antagonist for at least four weeks unless not possible due to renal function or serum potassium.

2. For female subjects, the following conditions must be met:

   1. postmenopausal status for at least one year, or
   2. status post-surgical sterilization

Exclusion Criteria:

1. History of hypersensitivity or allergy to any of the study drugs, drugs of similar chemical classes, ACEi, ARBs, or NEPi, as well as known or suspected contraindications to the study drugs
2. History of angioedema
3. History of pancreatitis or known pancreatic lesions
4. History of decompensated HF within the last six months (exacerbation of chronic HF manifested by signs and symptoms that required intravenous therapy or hospitalization)
5. History of heart transplant or on a transplant list or with left ventricular assistance device
6. Symptomatic hypotension and/or a SBP<100 mmHg at screening or <90 mmHg during the study
7. Serum potassium >5.2 mmol/L at screening or >5.4 mmol/L during the study
8. Acute coronary syndrome, cardiac, carotid, or other major cardiovascular surgery, percutaneous coronary intervention, or carotid angioplasty within six months prior to screening
9. Coronary or carotid artery disease likely to require surgical or percutaneous intervention within six months of screening
10. History of serious neurologic disease such as cerebral hemorrhage, stroke, seizure, or transient ischemic attack within six months
11. History of ventricular arrhythmia with syncopal episodes
12. Symptomatic bradycardia or second- or third-degree atrioventricular block without a pacemaker
13. Presence of hemodynamically significant mitral and/or aortic valve disease, except mitral regurgitation secondary to LV dilatation
14. Presence of other hemodynamically significant obstructive lesions of the left ventricular outflow tract, including aortic and subaortic stenosis
15. Type 1 diabetes
16. Poorly controlled type 2 diabetes mellitus (T2DM), defined as a HgbA1c >9%
17. Hematocrit <35%

18. Impaired renal function (eGFR of <30mL/min/1.73 m2) as determined by the four-variable Modification of Diet in Renal Disease (MDRD) equation, where serum creatinine (Scr) is expressed in mg/dL and age in years:

    eGFR (mL/min/1.73m2)=175 • Scr-1.154 • age-0.203 • (1.212 if Black) • (0.742 if female)

19. Use of hormone-replacement therapy
20. Breast feeding and pregnancy
21. History or presence of immunological or hematological disorders
22. History of malignancy other than non-melanoma skin cancer
23. Diagnosis of asthma requiring use of inhaled beta agonist more than once a week
24. Clinically significant gastrointestinal impairment that could interfere with drug absorption
25. Impaired hepatic function [aspartate amino transaminase (AST) and/or alanine amino transaminase (ALT) >3.0 x upper limit of normal range]
26. Any underlying or acute disease requiring regular medication which could possibly pose a threat to the subject or make implementation of the protocol or interpretation of the study results difficult, such as arthritis treated with non-steroidal anti-inflammatory drugs
27. Treatment with chronic systemic glucocorticoid therapy within the last year
28. Treatment with lithium salts
29. History of alcohol or drug abuse
30. Treatment with any investigational drug in the one month preceding the study
31. Mental conditions rendering the subject unable to understand the nature, scope, and possible consequences of the study
32. Inability to comply with the protocol, e.g., uncooperative attitude, inability to return for follow-up visits, and unlikelihood of completing the study

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Basic Science
• Allocation: Randomized
• Interventional Model: Crossover Assignment
• Masking: Quadruple

Number of Arms

12

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: S/V+Pla, S/V+I, Enal+Pla, Enal+I; Enal indicated Enalapril 10 mg bid for seven days, and S/V indicates Sacubitril-Valsartan 200 mg bid for seven days. Pla indicates intravenous placebo given on the seventh day of treatment, whereas I indicates intravenous icatibant given on the seventh day of treatment. Each treatment period is separated by a three-week washout during which patients receive Valsartan 80 mg bid.	Drug: Valsartan 80 mg bid; oral medication during run-in and washout period; Drug: Enalapril 10 mg bid; oral medication; Drug: Sacubitril-Valsartan 200 mg bid; oral medication; Drug: Icatibant; intravenous medication; Drug: Placebo; intravenous medication
Experimental: S/V+Pla, Enal+I, S/V+I, Enal+Pla; Enal indicated Enalapril 10 mg bid for seven days, and S/V indicates Sacubitril-Valsartan 200 mg bid for seven days. Pla indicates intravenous placebo given on the seventh day of treatment, whereas I indicates intravenous icatibant given on the seventh day of treatment. Each treatment period is separated by a three-week washout during which patients receive Valsartan 80 mg bid.	Drug: Valsartan 80 mg bid; oral medication during run-in and washout period; Drug: Enalapril 10 mg bid; oral medication; Drug: Sacubitril-Valsartan 200 mg bid; oral medication; Drug: Icatibant; intravenous medication; Drug: Placebo; intravenous medication
Experimental: S/V+Pla, Enal+Pla, Enal+I, S/V+I; Enal indicated Enalapril 10 mg bid for seven days, and S/V indicates Sacubitril-Valsartan 200 mg bid for seven days. Pla indicates intravenous placebo given on the seventh day of treatment, whereas I indicates intravenous icatibant given on the seventh day of treatment. Each treatment period is separated by a three-week washout during which patients receive Valsartan 80 mg bid.	Drug: Valsartan 80 mg bid; oral medication during run-in and washout period; Drug: Enalapril 10 mg bid; oral medication; Drug: Sacubitril-Valsartan 200 mg bid; oral medication; Drug: Icatibant; intravenous medication; Drug: Placebo; intravenous medication
Experimental: S/V+I, S/V+Pla, Enal+I, Enal+P; Enal indicated Enalapril 10 mg bid for seven days, and S/V indicates Sacubitril-Valsartan 200 mg bid for seven days. Pla indicates intravenous placebo given on the seventh day of treatment, whereas I indicates intravenous icatibant given on the seventh day of treatment. Each treatment period is separated by a three-week washout during which patients receive Valsartan 80 mg bid.	Drug: Valsartan 80 mg bid; oral medication during run-in and washout period; Drug: Enalapril 10 mg bid; oral medication; Drug: Sacubitril-Valsartan 200 mg bid; oral medication; Drug: Icatibant; intravenous medication; Drug: Placebo; intravenous medication
Experimental: S/V+I, Enal+Pla, S/V+Pla, Enal+I; Enal indicated Enalapril 10 mg bid for seven days, and S/V indicates Sacubitril-Valsartan 200 mg bid for seven days. Pla indicates intravenous placebo given on the seventh day of treatment, whereas I indicates intravenous icatibant given on the seventh day of treatment. Each treatment period is separated by a three-week washout during which patients receive Valsartan 80 mg bid.	Drug: Valsartan 80 mg bid; oral medication during run-in and washout period; Drug: Enalapril 10 mg bid; oral medication; Drug: Sacubitril-Valsartan 200 mg bid; oral medication; Drug: Icatibant; intravenous medication; Drug: Placebo; intravenous medication
Experimental: S/V+I, Enal+I, Enal+Pla, S/V+Pla; Enal indicated Enalapril 10 mg bid for seven days, and S/V indicates Sacubitril-Valsartan 200 mg bid for seven days. Pla indicates intravenous placebo given on the seventh day of treatment, whereas I indicates intravenous icatibant given on the seventh day of treatment. Each treatment period is separated by a three-week washout during which patients receive Valsartan 80 mg bid.	Drug: Valsartan 80 mg bid; oral medication during run-in and washout period; Drug: Enalapril 10 mg bid; oral medication; Drug: Sacubitril-Valsartan 200 mg bid; oral medication; Drug: Icatibant; intravenous medication; Drug: Placebo; intravenous medication
Experimental: Enal+Pla, S/V+Pla, S/V+I, Enal+I; Enal indicated Enalapril 10 mg bid for seven days, and S/V indicates Sacubitril-Valsartan 200 mg bid for seven days. Pla indicates intravenous placebo given on the seventh day of treatment, whereas I indicates intravenous icatibant given on the seventh day of treatment. Each treatment period is separated by a three-week washout during which patients receive Valsartan 80 mg bid.	Drug: Valsartan 80 mg bid; oral medication during run-in and washout period; Drug: Enalapril 10 mg bid; oral medication; Drug: Sacubitril-Valsartan 200 mg bid; oral medication; Drug: Icatibant; intravenous medication; Drug: Placebo; intravenous medication
Experimental: Enal+Pla, S/V+I, Enal+I, S/V+Pla; Enal indicated Enalapril 10 mg bid for seven days, and S/V indicates Sacubitril-Valsartan 200 mg bid for seven days. Pla indicates intravenous placebo given on the seventh day of treatment, whereas I indicates intravenous icatibant given on the seventh day of treatment. Each treatment period is separated by a three-week washout during which patients receive Valsartan 80 mg bid.	Drug: Valsartan 80 mg bid; oral medication during run-in and washout period; Drug: Enalapril 10 mg bid; oral medication; Drug: Sacubitril-Valsartan 200 mg bid; oral medication; Drug: Icatibant; intravenous medication; Drug: Placebo; intravenous medication
Experimental: Enal+Pla, Enal+I, S/V+Pla, S/V+I; Enal indicated Enalapril 10 mg bid for seven days, and S/V indicates Sacubitril-Valsartan 200 mg bid for seven days. Pla indicates intravenous placebo given on the seventh day of treatment, whereas I indicates intravenous icatibant given on the seventh day of treatment. Each treatment period is separated by a three-week washout during which patients receive Valsartan 80 mg bid.	Drug: Valsartan 80 mg bid; oral medication during run-in and washout period; Drug: Enalapril 10 mg bid; oral medication; Drug: Sacubitril-Valsartan 200 mg bid; oral medication; Drug: Icatibant; intravenous medication; Drug: Placebo; intravenous medication
Experimental: Enal+I, S/V+Pla, Enal+Pla, S/V+I; Enal indicated Enalapril 10 mg bid for seven days, and S/V indicates Sacubitril-Valsartan 200 mg bid for seven days. Pla indicates intravenous placebo given on the seventh day of treatment, whereas I indicates intravenous icatibant given on the seventh day of treatment. Each treatment period is separated by a three-week washout during which patients receive Valsartan 80 mg bid.	Drug: Valsartan 80 mg bid; oral medication during run-in and washout period; Drug: Enalapril 10 mg bid; oral medication; Drug: Sacubitril-Valsartan 200 mg bid; oral medication; Drug: Icatibant; intravenous medication; Drug: Placebo; intravenous medication
Experimental: Enal+I, S/V+I, S/V+Pla, Enal+Pla; Enal indicated Enalapril 10 mg bid for seven days, and S/V indicates Sacubitril-Valsartan 200 mg bid for seven days. Pla indicates intravenous placebo given on the seventh day of treatment, whereas I indicates intravenous icatibant given on the seventh day of treatment. Each treatment period is separated by a three-week washout during which patients receive Valsartan 80 mg bid.	Drug: Valsartan 80 mg bid; oral medication during run-in and washout period; Drug: Enalapril 10 mg bid; oral medication; Drug: Sacubitril-Valsartan 200 mg bid; oral medication; Drug: Icatibant; intravenous medication; Drug: Placebo; intravenous medication
Experimental: Enal+I, Enal+Pla, S/V+I, S/V+Pla; Enal indicated Enalapril 10 mg bid for seven days, and S/V indicates Sacubitril-Valsartan 200 mg bid for seven days. Pla indicates intravenous placebo given on the seventh day of treatment, whereas I indicates intravenous icatibant given on the seventh day of treatment. Each treatment period is separated by a three-week washout during which patients receive Valsartan 80 mg bid.	Drug: Valsartan 80 mg bid; oral medication during run-in and washout period; Drug: Enalapril 10 mg bid; oral medication; Drug: Sacubitril-Valsartan 200 mg bid; oral medication; Drug: Icatibant; intravenous medication; Drug: Placebo; intravenous medication

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
change in systolic blood pressure	7-hour period after 7-day intervention
change in plasma cGMP	7-hour period after 7-day intervention

Secondary Outcome Measures

Outcome Measure	Time Frame
heart rate	7-hour period after 7-day intervention
renal plasma flow	7-hour period after 7-day intervention
glomerular filtration rate	7-hour period after 7-day intervention
change in diastolic blood pressure	7-hour period after 7-day intervention
fractional excretion of sodium	7-hour period after 7-day intervention
urine albumin-to-creatinine ratio	7-hour period after 7-day intervention
brain natriuretic peptide (BNP) to N-terminal pro-BNP ratio	7-hour period after 7-day intervention
plasminogen activator inhibitor-1	7-hour period after 7-day intervention
tissue plasminogen activator	7-hour period after 7-day intervention
aldosterone	7-hour period after 7-day intervention
urine cGMP	7-hour period after 7-day intervention

Collaborators and Investigators

• Sponsor: Vanderbilt University Medical Center

Study record dates

Study Major Dates

• Study Start (Anticipated): September 1, 2017
• Primary Completion (Anticipated): January 1, 2020
• Study Completion (Anticipated): January 1, 2020

Study Registration Dates

• First Submitted: December 22, 2016
• First Submitted That Met QC Criteria: December 22, 2016
• First Posted (Estimate): December 29, 2016

Study Record Updates

• Last Update Posted (Actual): January 11, 2018
• Last Update Submitted That Met QC Criteria: January 9, 2018
• Last Verified: January 1, 2018

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Heart Diseases; Cardiovascular Diseases; Heart Failure; Physiological Effects of Drugs; Molecular Mechanisms of Pharmacological Action; Antihypertensive Agents; Peripheral Nervous System Agents; Enzyme Inhibitors; Analgesics; Sensory System Agents; Anti-Inflammatory Agents, Non-Steroidal; Analgesics, Non-Narcotic; Anti-Inflammatory Agents; Antirheumatic Agents; Immunosuppressive Agents; Immunologic Factors; Protease Inhibitors; Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Complement Inactivating Agents; Bradykinin B2 Receptor Antagonists; Bradykinin Receptor Antagonists; Valsartan; Enalapril; Sacubitril and valsartan sodium hydrate drug combination; Icatibant
• Other Study ID Numbers: IRB#161306

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No